INTRINSIC RV - Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs
This study has been completed.
Sponsor:
Boston Scientific Corporation
Information provided by:
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT00148967
First received: September 7, 2005
Last updated: November 20, 2006
Last verified: November 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
INTRINSIC RV is a two-armed randomized trial that will compare the effects of innovative dual-chamber pacing with AV Search Hysteresis to standard VVI among ICD patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Tachycardia |
Device: Implantable Cardioverter Defibrillator |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs |
Resource links provided by NLM:
Further study details as provided by Boston Scientific Corporation:
Primary Outcome Measures:
- Demonstrate that DDDR-AVSH is as effective as VVI with respect to the composite endpoint of death or heart failure hospitalizations.
Secondary Outcome Measures:
- The following variables will be compared between patients who are randomized to either DDDR-AVSH or VVI:
- The prevalence of atrial fibrillation, Changes in medication dosage, including beta-blocker, anti-arrhythmic and coumadin medications, Programming changes, Quality of life
| Estimated Enrollment: | 1535 |
| Study Start Date: | July 2003 |
| Estimated Study Completion Date: | October 2005 |
The purpose of study is to assess whether AVSH will provide benefits of a dual-chamber ICD without the deleterious effects of unnecessary RV pacing. This study will aim to demonstrate that DDDR-AVSH is equal to VVI with respect to mortality and HF hospitalizations.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- Patients who meet VITALITY™AVT® ICD indications
- Patients who sign and date a Patient Informed Consent prior to device implant
- Patients who remain in the clinical care of the enrolling physician
Exclusion Criteria:
- Patients with current indication for CRT-D
- Patients who previously had a pacemaker, ICD or CRT-D
- Patients with chronic AF
- Patients whose life expectancy is <12 months due to other medical conditions
- Patients who are expected to receive a heart transplant during the duration of the study
- Patients with epicardial pacing leads
- Patients who have CABG, PCI, cardiac or other arrhythmia surgery planned but not yet performed
- Patients with or who are likely to receive a tricuspid or other valve prosthesis
- Patients who are currently enrolled in another investigational study that would directly impact the treatment or outcome of the current study
- Patients who are younger than 18 years of age
- Patients who are pregnant
- Patients who are mentally incompetent and cannot give Patient Informed Consent or participate in the study
Contacts and Locations
More Information
No publications provided by Boston Scientific Corporation
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00148967 History of Changes |
| Other Study ID Numbers: | CR-CA-051403-T |
| Study First Received: | September 7, 2005 |
| Last Updated: | November 20, 2006 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Boston Scientific Corporation:
|
right ventricular pacing implantable cardioverter defibrillator |
Additional relevant MeSH terms:
|
Tachycardia Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013